Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: The RED-CABG randomized controlled trial

JAMA

Volumn 308, Issue 2, 2012, Pages 157-164

  Newman, Mark F ^a   Ferguson, T Bruce ^b   White, Jennifer A ^a   Ambrosio, Giuseppe ^c   Koglin, Joerg ^d   Nussmeier, Nancy A ^e   Pearl, Ronald G ^f   Pitt, Bertram ^g   Wechsler, Andrew S ^h   Weisel, Richard D ⁱ   Reece, Tammy L ^a   Lira, Armando ^d   Harrington, Robert A ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b East Carolina Heart Institute   (United States)

^c UNIVERSITY OF PERUGIA   (Italy)

^d MERCK RESEARCH LABORATORIES   (United States)

^e SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE;

AGED; ARTICLE; ARTIFICIAL VENTILATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RESPONSE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NONFATAL STROKE; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STROKE;

EID: 84863689054     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.7633     Document Type: Article

References (34)

1. STS National Database. Society of Thoracic Surgeons website. http://www.sts.org/national -database. Accessed June 24, 2011.
2. Clark RE; Ad HocCommittee on Cardiac Surgery Credentialing of the Society of Thoracic Surgeons. Outcome as a function of annual coronary artery bypass graft volume. Ann Thorac Surg. 1996;61(1):21-26.
3. Del Rizzo DF, Fremes SE, Christakis GT, Sever J, Goldman BS. The current status of myocardial revascularization: changing trends and risk factor analysis. J Card Surg. 1996;11(1):18-29. (Pubitemid 26088075)
4. Edwards FH, Clark RE, Schwartz M. Coronary artery bypass grafting: the Society of Thoracic Surgeons National Database experience. Ann Thorac Surg. 1994;57(1):12-19. (Pubitemid 24047685)
5. Edwards FH, Clark RE, Schwartz M. Impact of internal mammary artery conduits on operative mortality in coronary revascularization. Ann Thorac Surg. 1994;57(1):27-32. (Pubitemid 24047687)
6. He GW, Acuff TE, Ryan WH, Bowman RT, Douthit MB, Mack MJ. Determinants of operative mortality in elderly patients undergoing coronary artery bypass grafting: emphasis on the influence of internal mammary artery grafting on mortality and morbidity. J Thorac Cardiovasc Surg. 1994;108(1):73-81. (Pubitemid 24224260)
7. Jones RH, Hannan EL, Hammermeister KE, et al Working Group Panel on the Cooperative CABG Database Project. Identification of preoperative variables needed for risk adjustment of short-term mortality after coronary artery bypass graft surgery. J Am Coll Cardiol. 1996;28(6):1478-1487. (Pubitemid 26391853)
8. Magovern JA, Sakert T, Magovern GJ, et al. A model that predicts morbidity and mortality after coronary artery bypass graft surgery. J Am Coll Cardiol. 1996; 28(5):1147-1153. (Pubitemid 26376987)
9. Mangano DT; Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002; 347(17):1309-1317.
10. O'Connor GT, Plume SK, Olmstead EM, et al Northern New England Cardiovascular Disease Study Group. A regional intervention to improve the hospital mortality associated with coronary artery bypass graft surgery. JAMA. 1996;275(11):841-846. (Pubitemid 26087220)
11. Tu JV, Jaglal SB, Naylor CD; Steering Committee of the Provincial Adult Cardiac Care Network of Ontario. Multicenter validation of a risk index for mortality, intensive care unit stay, and overall hospital length of stay after cardiac surgery. Circulation. 1995; 91(3):677-684.
12. Ferguson TB Jr, Hammill BG, Peterson ED, DeLong ER, Grover FL; STS National Database Committee; Society of Thoracic Surgeons. A decade of change-risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990-1999: a report from the STS National Database Committee and the Duke Clinical Research Institute. Ann Thorac Surg. 2002;73(2):480-490.
13. Guru V, Tu JV, Etchells E, et al. Relationship between preventability of death after coronary artery bypass graft surgery and all-cause risk-adjusted mortality rates. Circulation. 2008;117(23):2969-2976.
14. O'Connor GT, Birkmeyer JD, Dacey LJ, et al Northern New England Cardiovascular Disease Study Group. Results of a regional study of modes of death associated with coronary artery bypass grafting. Ann Thorac Surg. 1998;66(4):1323-1328. (Pubitemid 28518072)
15. Mentzer RM Jr, Bartels C, Bolli R, et al EXPEDITION Study Investigators. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg. 2008;85(4):1261-1270. (Pubitemid 351381652)
16. Alexander JH, Emery RW Jr, Carrier M, et al; MEND-CABG II Investigators. Efficacy and safety of pyridoxal 5′-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial. JAMA. 2008;299(15):1777-1787. (Pubitemid 351549969)
17. Verrier ED, Shernan SK, Taylor KM, et al PRIMOCABG Investigators. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA. 2004;291(19):2319-2327. (Pubitemid 38656298)
18. Ikonomidis JS, Shirai T, Weisel RD, et al. Preconditioning cultured human pediatric myocytes requires adenosine and protein kinase C. Am J Physiol. 1997;272(3, pt 2):H1220-H1230.
19. Mentzer RM Jr, Birjiniuk V, Khuri S, et al. Adenosine myocardial protection: preliminary results of a phase II clinical trial. Ann Surg. 1999;229(5):643-650. (Pubitemid 30187571)
20. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002;4(4):266-273. (Pubitemid 34716307)
21. Gadalla AE, Pearson T, Currie AJ, et al. AICA riboside both activates AMP-activated protein kinase and competes with adenosine for the nucleoside transporter in the CA1 region of the rat hippocampus. J Neurochem. 2004;88(5):1272-1282. (Pubitemid 38280695)
22. Gruber HE, Hoffer ME, McAllister DR, et al. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside: effects on flow, granulocytes, and injury. Circulation. 1989;80(5):1400-1411. (Pubitemid 19282530)
23. Guigas B, Sakamoto K, Taleux N, et al. Beyond AICA riboside: in search of new specific AMP-activated protein kinase activators. IUBMB Life. 2009;61(1):18-26.
24. Iglesias MA, Furler SM, Cooney GJ, Kraegen EW, Ye JM. AMP-activated protein kinase activation by AICAR increases both muscle fatty acid and glucose uptake in white muscle of insulin-resistant rats in vivo. Diabetes. 2004;53(7):1649-1654. (Pubitemid 38857020)
25. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol. 2007;47:185-210.
26. Reznick RM, Zong H, Li J, et al. Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab. 2007;5(2):151-156. (Pubitemid 46172924)
27. Mangano DT; Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Effects of acadesine on myocardial infarction, stroke, and death following surgery: a meta-analysis of the 5 international randomized trials. JAMA. 1997;277(4):325-332.
28. Schweikert B, Hahmann H, Leidl R. Validation of the EuroQol questionnaire in cardiac rehabilitation. Heart. 2006;92(1):62-67. (Pubitemid 43021857)
29. Eagle KA, Guyton RA, Davidoff R, et al American College of Cardiology; American Heart Association. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation. 2004;110(14):e340-e437.
30. Shahian DM, O'Brien SM, Filardo G, et al Society of Thoracic Surgeons Quality Measurement Task Force. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1-coronary artery bypass grafting surgery. Ann Thorac Surg. 2009;88(1)(suppl):S2-S22.
31. Tardif JC, Carrier M, Kandzari DE, et al MENDCABG Investigators. Effects of pyridoxal-5′-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MENDCABG randomized study. J Thorac Cardiovasc Surg. 2007;133(6):1604-1611.
32. Davierwala PM, Maganti M, Yau TM. Decreasing significance of left ventricular dysfunction and reoperative surgery in predicting coronary artery bypass grafting - associated mortality: a twelve-year study. J Thorac Cardiovasc Surg. 2003;126(5):1335-1344. (Pubitemid 37449159)
33. Cohen DJ, Van Hout B, Serruys PW, et al Synergy Between PCI With Taxus and Cardiac Surgery Investigators. Quality of life after PCI with drugeluting stents or coronary-artery bypass surgery.NEngl J Med. 2011;364(11):1016-1026.
34. Grady KL, Lee R, Subačius H, et al. Improvements in health-related quality of life before and after isolated cardiac operations. Ann Thorac Surg. 2011;91(3):777-783.